Literature DB >> 3532942

Imipenem-cilastatin as initial therapy for febrile cancer patients.

G P Bodey, M E Alvarez, P G Jones, K V Rolston, L Steelhammer, V Fainstein.   

Abstract

Imipenem-cilastatin was used to treat 79 febrile episodes in 71 cancer patients, most of whom had neutropenia. The overall response rate was 67%, and 76% of the 45 documented infections responded. The response rates for septicemias and pneumonias were 79 and 62%, respectively. Only 1 of the 17 infections caused by gram-negative bacilli failed to respond to this therapy. The most common side effects were skin rash, nausea, and diarrhea. Eight superinfections were detected during therapy.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3532942      PMCID： PMC180520          DOI： 10.1128/AAC.30.2.211

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  21 in total

1.  In vitro effectiveness of kanamycin and kanamycin/cephalothin against Klebsiella. Comparison with other antibiotics.

Authors:  R J Bulger
Journal:  Ann Intern Med       Date:  1967-09       Impact factor: 25.391

2.  Therapy with carbenicillin and gentamicin for patients with cancer and severe infections caused by gram-negative rods.

Authors:  J Klastersky; R Cappel; D Daneau
Journal:  Cancer       Date:  1973-02       Impact factor: 6.860

3.  Antibiotic combinations for infections in neutropenic patients. Evaluaton of carbenicillin plus either cephalothin or kanamycin.

Authors:  E L Middleman; A Watanabe; H Kaizer; G P Bodey
Journal:  Cancer       Date:  1972-08       Impact factor: 6.860

Review 4.  Imipenem: first of a new class of beta-lactam antibiotics.

Authors:  M Barza
Journal:  Ann Intern Med       Date:  1985-10       Impact factor: 25.391

5.  In vitro activity of thienamycin.

Authors:  F P Tally; N V Jacobus; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

6.  Gram-negative infections in cancer. Study of empiric therapy comparing carbenicillin-cephalothin with and without gentamicin.

Authors:  J Klastersky; A Henri; C Hensgens; D Daneau
Journal:  JAMA       Date:  1974-01-07       Impact factor: 56.272

7.  Therapy of neutropenic rats infected with Pseudomonas aeruginosa.

Authors:  R M Lumish; C W Norden
Journal:  J Infect Dis       Date:  1976-05       Impact factor: 5.226

8.  A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients.

Authors:  G P Bodey; S J Ketchel; V Rodriguez
Journal:  Am J Med       Date:  1979-10       Impact factor: 4.965

9.  Use of trimethoprim-sulfamethoxazole for treatment of infections in patients with cancer.

Authors:  G P Bodey; W E Grose; M J Keating
Journal:  Rev Infect Dis       Date:  1982 Mar-Apr

10.  Carbenicillin-trimethoprim/sulfamethoxazole versus carbenicillin-gentamicin as empiric therapy of infection in granulocytopenic patients. A prospective, randomized, double-blind study.

Authors:  R K Stuart; H G Braine; P S Lietman; R Saral; D J Fuller
Journal:  Am J Med       Date:  1980-06       Impact factor: 4.965
View more
  12 in total

1.  Comparison of two antibiotic regimens (piperacillin plus amikacin versus ceftazidime plus amikacin) as empiric therapy for febrile neutropenic patients with cancer.

Authors:  J Feliu; A Artal; M González Barón; A Berrocal; I Chacón; M L García de Paredes; E Espinosa; A Ordóñez; P Zamora; J M Montero
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

2.  Pseudomonas maltophilia infections in neutropenic patients and the use of imipenem.

Authors:  K G Kerr; P M Hawkey; J A Child; D R Norfolk; A W Anderson
Journal:  Postgrad Med J       Date:  1990-12       Impact factor: 2.401

Review 3.  Antibiotic combinations: should they be tested?

Authors:  G M Eliopoulos; C T Eliopoulos
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

4.  Imipenem and meropenem: Comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effects.

Authors:  G G Zhanel; A E Simor; L Vercaigne; L Mandell
Journal:  Can J Infect Dis       Date:  1998-07

5.  Single agent therapy for infections in cancer patients: a prospective randomized trial comparing three extended-spectrum cephalosporins.

Authors:  K V Rolston; P G Jones; V Fainstein; N M Khardori; E J Anaissie; L Steelhammer; G P Bodey
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-03       Impact factor: 3.267

6.  Ceftazidime versus imipenem-cilastatin as initial monotherapy for febrile neutropenic patients.

Authors:  R Liang; R Yung; E Chiu; P Y Chau; T K Chan; W K Lam; D Todd
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

7.  Ceftriaxone versus aztreonam plus cefazolin for infections in cancer patients with adequate neutrophil counts.

Authors:  F Menichetti; A Del Favero; G Bucaneve; V Minotti; L Patoia; S Pauluzzi
Journal:  Infection       Date:  1990 May-Jun       Impact factor: 3.553

Review 8.  Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  S P Clissold; P A Todd; D M Campoli-Richards
Journal:  Drugs       Date:  1987-03       Impact factor: 9.546

9.  Amikacin and ceftazidime as empirical antibiotic therapy in severely neutropenic patients: analysis of prognostic factors.

Authors:  F Rossini; P Pioltelli; S Mingozzi; R Bregani; F Viganó; S Bolis; I Casaroli; E Lanzi; E M Pogliani; G Corneo
Journal:  Support Care Cancer       Date:  1994-07       Impact factor: 3.603

10.  Evaluation of an immunofluorescent-antibody test for rapid identification of Pseudomonas aeruginosa in blood cultures.

Authors:  G W Counts; R W Schwartz; B K Ulness; D J Hamilton; M J Rosok; M D Cunningham; M R Tam; R P Darveau
Journal:  J Clin Microbiol       Date:  1988-06       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.